Clinical Trial Update: Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating lapatinib ditosylate in patients with metastatic or recurrent head and neck cancer has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma
• Salivary Gland Cancer
• Squamous Cell Carcinoma of the Hypopharynx
• Squamous Cell Carcinoma of the Larynx
• Squamous Cell Carcinoma of the Lip
• Squamous Cell Carcinoma of the Nasopharynx
• Squamous Cell Carcinoma of the Oral Cavity
• Squamous Cell Carcinoma of the Oropharynx

Drugs mentioned

• Lapatinib Ditosylate (lapatinib ditosylate)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx | Phase 2 | Status: COMPLETED